Multiple System Atrophy Pipeline Gains Momentum with 22+ Therapies in Development, Led by H. Lundbeck, Alterity Therapeutics, and AskBio | DelveInsight

The Multiple System Atrophy (MSA) therapeutic landscape is entering a transformative phase, driven by a surge in innovative drug development and increased scientific focus on disease-modifying approaches. Emerging players such as H. Lundbeck A/S, Alterity Therapeutics, AskBio, Cytora Ltd., and others are actively advancing novel therapies aimed at addressing the significant unmet needs in this rare neurodegenerative disorder.

DelveInsight's latest report, "Multiple System Atrophy Pipeline Insight, 2026," offers a comprehensive analysis of over 20 leading companies and 22+ pipeline drugs shaping the future of MSA treatment. The report delivers in-depth insights into clinical and preclinical drug candidates, therapeutic strategies, and pipeline segmentation based on product type, development stage, route of administration, and molecule type. It also evaluates inactive and discontinued programs, providing a holistic view of the evolving MSA pipeline ecosystem.

Explore the complete pipeline landscape and uncover growth opportunities in Multiple System Atrophy therapeutics: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Understanding Multiple System Atrophy: A Rare and Devastating Neurodegenerative Disorder
Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disease that affects multiple systems of the body, particularly those governing motor control and autonomic functions. The disease is marked by the accumulation of misfolded alpha-synuclein protein in glial cells, leading to widespread neuronal degeneration and dysfunction.

Clinically, Multiple System Atrophy is classified into two major subtypes:
• MSA-P (Parkinsonian type): Characterized by symptoms such as rigidity, bradykinesia, tremors, and postural instability.
• MSA-C (Cerebellar type): Dominated by impaired coordination, gait disturbances, slurred speech, and abnormal eye movements.

Patients often experience a combination of motor and non-motor symptoms, including orthostatic hypotension, urinary dysfunction, and respiratory complications. The disease progression is typically rapid, with significant decline in quality of life.

Diagnosing Multiple System Atrophy remains challenging due to overlapping symptoms with other neurodegenerative disorders such as Parkinson's disease. Clinical evaluation, supported by imaging techniques like MRI and assessment of autonomic dysfunction, plays a critical role. However, definitive diagnosis is only possible through postmortem examination.

Currently, there is no cure for Multiple System Atrophy, and treatment is largely supportive, focusing on symptom management through pharmacological interventions, physiotherapy, speech therapy, and lifestyle modifications. This significant unmet need has catalyzed extensive research into disease-modifying therapies.

Evolving Multiple System Atrophy Pipeline Landscape: Innovation at the Forefront
The MSA pipeline is witnessing a paradigm shift, fueled by advancements in neurobiology, protein aggregation research, and gene therapy technologies. Drug developers are increasingly targeting the underlying disease mechanisms, particularly alpha-synuclein aggregation, neuroinflammation, and neuronal degeneration.

With over 20 companies actively engaged in research and development and more than 22 therapeutic candidates in the pipeline, the MSA landscape reflects growing momentum. These therapies span a wide spectrum of modalities, including monoclonal antibodies, small molecules, gene therapies, and cell-based treatments.

Gain deeper insights into emerging therapies and clinical advancements in Multiple System Atrophy:
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Multiple System Atrophy Pipeline Report
• The MSA pipeline includes 22+ active drug candidates across various stages of development.
• Approximately 20+ companies are actively developing therapies targeting diverse mechanisms.
• Key Multiple System Atrophy Companies are Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences LTD, Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., Yoda Therapeutics Inc., and others
• Key Multiple System Atrophy Therapies are Amlenetug, ATH434, hOMSC300, AB-1005, CS10BR05, Foralumab, KM-819, ONO-2808, TEV-56286, PMN442, ION464, YA-101
• Increasing focus on alpha-synuclein targeting and neuroprotective strategies is reshaping treatment approaches.
• Advanced therapies such as gene therapy and stem cell-based interventions are gaining traction.
• Strategic collaborations, licensing agreements, and funding initiatives are accelerating pipeline progress.
• Orphan drug and fast track designations are supporting faster regulatory pathways.
• Precision medicine and biomarker-driven approaches are emerging as key trends.
• In March 2026, Lundbeck announced ahead-of-schedule completion of patient randomization in the Phase III MASCOT trial of amlenetug for MSA, with results expected in Q3 2027 and potential launch in Q1 2029.
• In December 2025, Lundbeck announced it will showcase the design of its Phase 3 MASCOT trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders. The trial evaluates amlenetug, an investigational monoclonal antibody targeting alpha-synuclein, for the treatment of Multiple System Atrophy (MSA). MSA is a rare, aggressive neurodegenerative disorder with no current disease-modifying treatments. The MASCOT study aims to determine if amlenetug can slow disease progression by preventing the aggregation of toxic proteins in the brain. This presentation will provide the medical community with key insights into the study's methodology and its potential impact on MSA patients.
• In December 2025,Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has completed enrollment for its Phase 1 clinical trial of AB-1005 for Multiple System Atrophy-Parkinsonian type (MSA-P). AB-1005 is an investigational gene therapy that uses an AAV2 vector to deliver the GDNF gene directly to the brain. This approach is intended to support the survival of neurons and potentially slow the progression of the disease. The study focuses on the safety and tolerability of the surgical delivery method. This milestone is a critical step in determining if gene therapy can offer a neuroprotective benefit for patients with this rapidly progressing condition.
• In December 2025, Teva Pharmaceutical Industries announced that the U.S. FDA has granted Fast Track Designation to emrusolmin for the treatment of Multiple System Atrophy (MSA). Emrusolmin is an oral small molecule designed to inhibit the aggregation of alpha-synuclein, a key driver of MSA pathology. Fast Track status is intended to expedite the development and review of drugs for serious conditions with unmet medical needs. This designation allows Teva to have more frequent interactions with the FDA and potentially qualify for Priority Review. The news marks a significant advancement in the effort to bring a disease-modifying therapy to the MSA community.
• In September 2025, Teva Pharmaceutical (NYSE:TEVA) announced that its investigational MSA treatment, emrusolmin, received Fast Track designation from the U.S. FDA. The drug is currently in Phase 2 development for Multiple System Atrophy.
• In August 2025, Tiziana Life Sciences received FDA clearance of its IND for a Phase 2a trial of intranasal foralumab in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved therapies. The six-month open-label study will evaluate microglial activation, clinical outcomes, and safety of the fully human anti-CD3 monoclonal antibody delivered via nasal spray.
• In July 2025, NKGen Biotech received FDA authorization for an Expanded Access Program (EAP) to use its NK cell therapy, troculeucel, in multiple neurodegenerative diseases-including Alzheimer's, Parkinson's, ALS, MSA, PSP, FTD, MS, and Lewy Body Dementia-beyond its current Phase 2a trial in moderate-stage Alzheimer's disease.

Multiple System Atrophy Emerging Drugs Profile
Amlenetug: H. Lundbeck A/S
Amlenetug (Lu AF82422) is a monoclonal antibody targeting extracellular alpha-synuclein, aiming to prevent its spread and promote immune-mediated clearance. With multiple regulatory designations, including FDA Fast Track and Orphan Drug status, the therapy is currently in Phase III clinical trials under the MASCOT study. Its mechanism represents a promising disease-modifying approach in MSA.

ATH434: Alterity Therapeutics
ATH434 is an oral small molecule designed to regulate iron distribution in the brain and inhibit alpha-synuclein aggregation. Having completed Phase II trials with encouraging results, the therapy is progressing toward Phase III development. Its neuroprotective potential positions it as a strong late-stage candidate.

hOMSC300: Cytora Ltd.
hOMSC300 is an allogeneic stem cell therapy with regenerative and anti-inflammatory properties. Delivered intrathecally, it aims to promote neuronal survival and repair. Currently in Phase I development, it represents a novel approach to disease modification in MSA.

AB-1005: AskBio
AB-1005 is an AAV2-based gene therapy delivering GDNF to support dopaminergic neuron function. Designed for MSA-P, it is currently in Phase I trials and highlights the growing role of gene therapy in neurodegenerative diseases.
Additional pipeline candidates such as CS10BR05, Foralumab, KM-819, ONO-2808, TEV-56286, PMN442, ION464, and YA-101 further enrich the pipeline with diverse mechanisms and therapeutic strategies.

Discover detailed Multiple System Atrophy drug profiles and clinical updates: https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Multiple System Atrophy Pipeline Segmentation and Therapeutic Assessment
The report provides a detailed segmentation of the MSA pipeline based on multiple parameters:
Multiple System Atrophy Clinical Development Stages
• Phase III (late-stage)
• Phase II (mid-stage)
• Phase I (early-stage)
• Preclinical and discovery-stage candidates
• Inactive and discontinued programs

Multiple System Atrophy Route of Administration
• Oral
• Intravenous
• Intrathecal
• Subcutaneous
• Parenteral
• Transdermal
• Topical
• Ophthalmic

Multiple System Atrophy Molecule Types
• Small molecules
• Peptides
• Oligonucleotides
• Gene therapies
• Cell therapies

Multiple System Atrophy Product Types
• Monotherapy
• Combination therapy
• Mono/combination approaches
This diverse segmentation highlights the complexity of MSA and the multifaceted strategies required to address it.

Gain strategic intelligence and competitive insights into Severe Asthma R&D:
: https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Multiple System Atrophy Clinical Trial and Development Activities
The MSA pipeline is characterized by increasing clinical trial activity across global regions. Companies are actively pursuing partnerships and collaborations to accelerate development timelines and enhance research capabilities.
Key players such as H. Lundbeck A/S, Alterity Therapeutics, and AskBio are leading late-stage and early-stage innovations, while emerging biotech firms are exploring cutting-edge approaches such as stem cell therapy and gene editing.
The report provides detailed insights into ongoing clinical trials, study designs, endpoints, and regulatory milestones, offering a comprehensive view of the competitive landscape.

Multiple System Atrophy Market Drivers, Challenges, and Future Outlook
Key Multiple System Atrophy Market Drivers
• Rising awareness and improved diagnosis of rare neurodegenerative diseases
• Advancements in neuroscience and molecular biology
• Strong regulatory support through orphan drug designations
• Increasing investment in rare disease research

Multiple System Atrophy Market Challenges
• Limited understanding of disease etiology
• Lack of reliable biomarkers for early diagnosis
• High clinical trial failure rates
• Small patient populations affecting trial design
Despite these challenges, the future outlook for MSA therapeutics remains highly promising. The integration of artificial intelligence, biomarker discovery, and personalized medicine is expected to significantly enhance drug development and patient outcomes.

Scope of the Multiple System Atrophy Pipeline Report
• Coverage: Global
• Key Multiple System Atrophy Companies: Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences LTD, Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., Yoda Therapeutics Inc., and others
• Key Multiple System Atrophy Therapies: Amlenetug, ATH434, hOMSC300, AB-1005, CS10BR05, Foralumab, KM-819, ONO-2808, TEV-56286, PMN442, ION464, YA-101
• Therapeutic Assessment: By product type, stage, route of administration, and molecule type

Request for free sample report:
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Questions Addressed in the Report
• How many companies are actively developing MSA therapies?
• What are the most advanced pipeline drugs?
• What are the key collaborations and licensing deals?
• What novel mechanisms are being explored?
• What is the current status of clinical trials?
• What regulatory designations have been granted?

Table of Contents
1. Introduction
2. Executive Summary
3. Multiple System Atrophy Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Analytical Perspective
7. Late-Stage Products
8. Mid-Stage Products
9. Early-Stage Products
10. Inactive Products
11. Key Companies
12. Key Products
13. Unmet Needs
14. Market Drivers and Barriers
15. Future Perspectives

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.